4-(1-甲基吡唑-4-基)苯磺酰氯 | 883146-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(1-甲基吡唑-4-基)苯磺酰氯
• 英文名称: 4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl chloride
• 英文别名: 4-(1-Methyl-1H-pyrazol-4-yl)benzenesulfonyl chloride；4-(1-methylpyrazol-4-yl)benzenesulfonyl chloride
• CAS: 883146-09-6
• 化学式: C₁₀H₉ClN₂O₂S
• 分子量: 256.713
• InChiKey: QAUCTDBYRKXERD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-甲基吡唑-4-基)苯磺酰氯 、 N³-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3,5-diamine 以 丙酮 为溶剂， 以39 %的产率得到1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)-N3-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3,5-diamine
  参考文献：
  名称：

  受天然产物启发发现三甲氧基苯基-1,2,4-三唑磺酰胺作为有效的微管蛋白聚合抑制剂

  摘要：

  一种独特的受天然产物启发的策略使得能够发现三甲氧基苯基-1,2,4-三唑并磺酰胺作为潜在的微管蛋白聚合抑制剂。开发了化学和区域选择性合成方法。化合物16被发现是微管蛋白聚合的有效抑制剂。它使细胞停滞在 G2/M 阶段并诱导多核细胞的形成，最终导致细胞死亡。

  DOI：

  10.1002/cmdc.202300562
• 作为产物：
  描述：

  1-甲基-4-苯基吡唑 在 氯磺酸 作用下， 以 氯仿 为溶剂， 以48 %的产率得到4-(1-甲基吡唑-4-基)苯磺酰氯
  参考文献：
  名称：

  受天然产物启发发现三甲氧基苯基-1,2,4-三唑磺酰胺作为有效的微管蛋白聚合抑制剂

  摘要：

  一种独特的受天然产物启发的策略使得能够发现三甲氧基苯基-1,2,4-三唑并磺酰胺作为潜在的微管蛋白聚合抑制剂。开发了化学和区域选择性合成方法。化合物16被发现是微管蛋白聚合的有效抑制剂。它使细胞停滞在 G2/M 阶段并诱导多核细胞的形成，最终导致细胞死亡。

  DOI：

  10.1002/cmdc.202300562

文献信息

• [EN] ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES AROMATIQUES D'ARYLSULFONYLMETHYLE OU D'ARYLSULFONAMIDE SUBSTITUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040178A1

  公开（公告）日：2006-04-20

  The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH2i O or S; E is CR6R7 or NR 3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-­alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4­-alkenyl, formyl or C,-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4 -cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及式(I)的芳香族化合物，其中Ar是苯基或芳香族5-或6-成员C-键合杂芳基，其中Ar可以携带1个基团Ra，Ar也可以携带1个或2个基团Rb；X是N或CH；Y是O、S、-CH=N-、-CH=CH-或-N=CH-；A是CH2i、O或S；E是CR6R7或NR3；R1是C1-C4-烷基、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-环烷基甲基、氟代C3-C4-烯基、甲酰基或C,-C3-烷基羰基；R1a是H、C2-C4-烷基、C3-C4-环烷基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基，或R1a和R2一起是(CH2)n，其中n为2或3，或R1a和R2a一起是(CH2)n，其中n为2或3；R2和R2a彼此独立地是H、CH3、CH2F、CHF2或CF3；R3是H或C1-C4-烷基；R6、R7彼此独立地选自H、C1-C2-烷基和氟代C1-C2-烷基；以及其生理耐受的酸盐。该发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗对多巴胺D3受体配体敏感的医疗疾病的药物组合物。
• [EN] AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES AMINOETHYLAROMATIQUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040179A1

  公开（公告）日：2006-04-20

  The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated Cl-C4­-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4­-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-­C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3­-C4-alkenyl, or R1a and R2 together are (CH2)n with n being 2, 3 or 4, or R1a and R2a together are (CH2)n with n being 2, 3 or 4; R2 and R2a are independently of each other H, C1-C4-alkyl or fluorinated C1-C4-alkyl or R2a and R2 together are (CH2)m with m being 1, 2, 3, 4 or 5; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及公式（I）的芳香族化合物，其中Ar为苯基或芳香族5-或6-成员C-键合杂环基，其中Ar可能携带1个基团Ra，Ar也可能携带1个或2个基团Rb；X为N或CH；E为CR6R7或NR3；R1为C1-C4-烷基，C3-C4-环烷基，C3-C4-环烷基甲基，C3-C4-烯基，氟代的Cl-C4-烷基，氟代的C3-C4-环烷基，氟代的C3-C4-环烷基甲基，氟代的C3-C4-烯基，甲酰基或C1-C3-烷基羰基；R1a为H，C1-C4-烷基，C3-C4-环烷基，C3-C4-环烷基甲基，C3-C4-烯基，氟代的C1-C4-烷基，氟代的C3-C4-环烷基，氟代的C3-C4-环烷基甲基，氟代的C3-C4-烯基，或R1a和R2一起为（CH2）n，其中n为2、3或4，或R1a和R2a一起为（CH2）n，其中n为2、3或4；R2和R2a彼此独立为H，C1-C4-烷基或氟代的C1-C4-烷基，或R2a和R2一起为（CH2）m，其中m为1、2、3、4或5；R3为H或C1-C4-烷基；R6、R7彼此独立地选自H、氟、C1-C4-烷基和氟代的C1-C4-烷基，或一起形成一个(CH2)p的基团，其中p为2、3、4或5；以及其生理耐受的酸盐。该发明还涉及使用公式（I）的化合物或其药学上可接受的盐来制备用于治疗可用多巴胺D3受体配体治疗的医疗疾病的药物组合物。
• [EN] HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES HETEROCYCLIQUES CONVENANT POUR TRAITER DES TROUBLES SENSIBLES A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040182A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6­ alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- ­membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4­alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  该发明涉及以下式(I)的化合物，其中n为0、1或2；G为CH2或CHR3；R1为H、C1-C6烷基、被C3-C6环烷基取代的C1-C6烷基、Cl-C6羟基烷基、氟化的C1-C6烷基、C3-C6环烷基、氟化的C3-C6环烷基、C3-C6烯基、氟化的C3-C6烯基、甲酰基、乙酰基或丙酰基；R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基；A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基，可以被卤素、甲基、甲氧基和CF3等一个或多个取代基取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基、含有1、2或3个异原子N、O和S的5-或6-元杂环芳基、以及与饱和或不饱和的5-或6-元碳环或杂环融合的苯基环组成的环状基，其中杂环环包含1、2或3个异原子N、O和S和/或1、2或3个异原子含氮基团，每个基团独立地选择自NR8，其中R8为H、C1-C4烷基、氟化的C1-C4烷基、C1-C4烷基酰基或氟化的C1-C4烷基酰基，环状基Ar可以携带1、2或3个取代基Ra，其中变量Ra具有权利要求和描述中给出的含义；以及其生理上可耐受的酸盐。该发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易受多巴胺D3受体配体治疗的医疗紊乱的药物组合物。
• [EN] AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES AROMATIQUES BICYCLIQUES AMINOMETHYLE SUBSTITUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040180A1

  公开（公告）日：2006-04-20

  The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula (I) wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; X is a covalent bond or N-R2, CHR2, CHR2CH2, N or C-R2; Y is N-R2a, CHR2a, CHR2aCH2 or CHR2aCH2CH2; is a single bond or a double bond; E is CH2 or NR3; R1 is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1­-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3­-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3­-C4-cycloalkyl, fluorinated C3-C4-alkenyl, R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3 or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2 or 3; R3 is H or C1-C4-alkyl; R4 and R5 independently of each other are H, C1-C4-alkyl, fluorinated C1-C4-alkyl or C1-C4­-alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R6 and R7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及一种氨甲基取代的双环芳香化合物，其化学式为(I)，其中Ar是从苯基、一个含有1、2或3个杂原子的5-或6成员C-键合杂芳基组成的环状基团中选择的循环基团，这些杂原子独立地选择自O、S和N，以及与饱和或不饱和的5-或6成员碳环或杂环融合的苯环，其中杂环包括作为环成员的1、2或3个选自N、O和S的杂原子和/或每个独立选择自NR8的1、2或3个含杂原子的基团，其中R8为H、C1-C4-烷基、氟代C1-C4-烷基、C1-C4-烷基酰基或氟代C1-C4-烷基酰基，环状基团Ar可能携带1、2或3个取代基Ra，其中变量Ra具有权利要求和描述中给定的含义；X是共价键或N-R2、CHR2、CHR2CH2、N或C-R2；Y是N-R2a、CHR2a、CHR2aCH2或CHR2aCH2CH2；是单键或双键；E是CH2或NR3；R1是H、C1-C4-烷基、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-环烷基甲基、氟代C3-C4-烯基、甲酰基或C1-C3-烷基酰基；R1a是H、C1-C4-烷基、C3-C4-环烷基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-烯基，R2和R2a各自独立地为H、CH3、CH2F、CHF2或CF3，或者R1a和R2或R1a和R2a一起为(CH2)n，其中n为1、2或3；R3为H或C1-C4-烷基；R4和R5独立地为H、C1-C4-烷基、氟代C1-C4-烷基或C1-C4-烷氧基，或者与N一起形成4、5或6成员饱和或不饱和环；R6和R7独立地为H或卤素；以及其生理耐受的酸盐加合物。该发明还涉及使用化合物(I)或其药学上可接受的盐制备用于治疗对多巴胺D3受体配体治疗敏感的医疗紊乱的药物组合物。
• [EN] AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES D'AZABICYCLOHEPTYLE DESTINES AU TRAITEMENT DES TROUBLES REAGISSANT A UNE MODULATION DU RECEPTEUR DE DOPAMINE D3
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040176A1

  公开（公告）日：2006-04-20

  The present invention relates to a compound of the formula (I) wherein R1 is H, C1-C6-alkyl which may be substituted by C3-C6-cycloalkyl, fluorinated C1-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6-alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1-C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra; wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及一种化合物，其化学式为（I），其中R1为H，C1-C6-烷基，可以被C3-C6-环烷基，氟代的C1-C6-烷基，C3-C6-环烷基，氟代的C3-C6-环烷基，C3-C6-烯基，氟代的C3-C6-烯基，甲酰基，乙酰基或丙酰基所取代；A为苯基，吡啶基，嘧啶基，吡嗪基，吡啶并嘧啶基或噻吩基，可以被卤素，甲基，甲氧基和CF3等一种或多种取代基所取代；E为NR5或CH2，其中R5为H或C1-C3-烷基；Ar为从苯基、一个含有1、2或3个氮、氧和硫的杂原子的5-或6-成员杂芳基团或一个与饱和或不饱和的5-或6-成员碳环或杂环团融合的苯环所选的环状基团，其中所述杂环团含有1、2或3个氮、氧和硫的杂原子和/或1、2或3个独立选择自NR8的含有杂原子基团，其中R8为H，C1-C4-烷基，氟代的C1-C4-烷基，C1-C4-烷基羰基或氟代的C1-C4-烷基羰基，环状基团Ar可以携带1、2或3个取代基Ra；其中变量Ra的含义如权利要求和说明书中所述；以及其生理耐受性酸盐。本发明还涉及使用化合物的式（I）或其药学上可接受的盐来制备用于治疗对多巴胺D3受体配体敏感的医疗疾病的药物组合物。